Roivant Sciences
Roivant Sciences develops transformative medicines and technologies through agile, focused companies called Vants, achieving 10 positive Phase 3 trials and 6 FDA approvals since 2019.
Roivant Sciences Overview
Roivant Sciences is a company focused on developing transformative medicines and technologies. It builds agile, focused companies known as Vants to accelerate drug development and commercialization. The company employs advanced technology across the entire lifecycle of drug discovery, development, and commercialization to bring new therapies to market efficiently.
Roivant Sciences Services
Roivant Sciences provides a range of services that include drug discovery, development, and commercialization. The company leverages advanced technological solutions to enhance efficiency and effectiveness at every stage of the drug development process. Roivant’s model aligns incentives to drive swift, high-quality execution and supports rigorous capital allocation practices.
Roivant Sciences FDA Approvals
Roivant Sciences has achieved significant milestones with six FDA approvals. These approvals highlight the company’s ability to successfully navigate the regulatory landscape and bring innovative therapies to patients. The focus on rigorous processes and technology ensures that the company maintains high standards in its drug development efforts.
VTAMA® Cream for Plaque Psoriasis
One of Roivant Sciences' notable products is VTAMA® (tapinarof) cream, 1%. This topical treatment is designed for adults with plaque psoriasis. The launch of VTAMA® underlines Roivant's commitment to addressing unmet medical needs through innovative therapeutic solutions.
Roivant Sciences Achievements in Clinical Trials
Since 2019, Roivant Sciences has conducted 10 positive Phase 3 trials, underscoring the company's strong track record in clinical research. These successful trials demonstrate Roivant’s dedication to maintaining high standards in the development of new therapies, ensuring they meet the efficacy and safety criteria required for regulatory approval.